Glycemic variability is associated with poor outcomes in pediatric hematopoietic stem cell transplant patients.

Just as with higher mean glucose, higher glycemic variability in the pediatric HSCT population is independently associated with significantly increased morbidity. Additional research is required to evaluate the utility of glucose control to mitigate these relationships and improve HSCT outcomes.